StockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to “Buy”

Royalty Pharma (NASDAQ:RPRX) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday.

A number of other research firms also recently weighed in on RPRX. The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target on the stock. in a report on Monday, June 3rd. Finally, Morgan Stanley raised their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Stock Up 1.9 %

RPRX stock opened at $28.26 on Tuesday. Royalty Pharma has a 12-month low of $25.20 and a 12-month high of $31.66. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The company has a market cap of $16.77 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 4.06 and a beta of 0.46. The company has a 50 day moving average of $27.85 and a two-hundred day moving average of $28.03.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same quarter in the prior year, the firm earned $0.85 EPS. On average, equities analysts anticipate that Royalty Pharma will post 4.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RPRX. Quadrant Capital Group LLC grew its stake in Royalty Pharma by 295.8% in the 4th quarter. Quadrant Capital Group LLC now owns 3,487 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 2,606 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in Royalty Pharma by 87.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 15,328 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 7,132 shares during the last quarter. ING Groep NV acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at about $1,298,000. Norges Bank acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at about $119,740,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at about $582,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.